Configurable multi-wavelength laser light engine for endoscopic fluorescence imaging

Ylöniemi, Zoe; Kaivosoja, Visa; Orsila, Lasse; Vierimaa, Tero; Uusimaa, Petteri

doi:10.1117/12.2608694

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modulight has experience from building versatile light engines for fluorescence imaging that could be utilized for this. [6] The excitation wavelength could be selected so that it is not only possible to visualize the tumor but also drug distribution over the tumor area to ensure that the drug is present in illuminated area to generate therapeutic response.…”

Section: Discussionmentioning

confidence: 99%

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

Ylöniemi

Kokko²,

Kaivosoja³

et al. 2023

Advanced Photonics in Urology 2023

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a high recurrence rate and limited treatment options. Currently best results are achieved when BCG (Bacillus Calmette-Guerin) is used together with photodynamic diagnosis (PDD) and TURBT (trans urethral resection of bladder tumor) but majority of NMIBC still recur after the initial treatment. Even though PDD is commonly used to visualize the lesions as part of a TURBT procedure, photosensitive drug compounds have had limited success in clinical setting partly because of limitations in light sources and light delivery optics.Modulight has extended its multi-indication laser platform to support the use of a novel photosensitive drug for NMIBC. The properties of different tumor types (papillary vs carcinoma in situ (CIS)) require different illumination methods and laser parameters and illumination modes have been defined accordingly. Laser system has been designed to support both focused illumination of localized lesions and overall illumination of the entire bladder to cover possible scattered CIS lesions. Light delivery system optimization has included compatibility testing with flexible cystoscopes and investigation of the light delivery system performance in bladder environment. Connectivity features of the laser system have been tailored to support documentation requirements in clinical trials by enabling treatment configuration and realized treatment log storage in Modulight cloud. Ongoing work and future plans include treatment monitoring and imaging capabilities integration in treatment flow with the aim to have a comprehensive laser platform that can support white light imaging, fluorescence imaging, and a variety of light-based treatment modalities

show abstract

Section: Discussionmentioning

confidence: 99%

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

Ylöniemi

Kokko²,

Kaivosoja³

et al. 2023

Advanced Photonics in Urology 2023

View full text Add to dashboard Cite

show abstract

“…In addition to PDT, the laser platform can also be equipped with wavelengths that are used for fluorophore activation, such as UV or blue light. Furthermore, the ML7710 laser platform has also been used for endoscopic fluorescent imaging applications with RGB illumination capabilities 10 .…”

Section: Ml7710 Laser Platformmentioning

confidence: 99%

Optimization of light delivery for non-muscle invasive bladder cancer PDT

Kokko

Perttilä²,

Ylöniemi³

et al. 2023

Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXXI

Self Cite

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light sources and light delivery optics. Bladder is somewhat challenging environment for PDT as it needs to be accessed cystoscopically and lesions might be difficult to target with traditional light delivery optics for example because of their close proximity to bladder entrance. The properties of different tumor types (papillary vs carcinoma in situ (CIS)) also require different illumination methods, so laser parameters and illumination modes need to be designed accordingly. Modulight has developed its ML7710 laser platform further to optimally support a novel photosensitive drug for treatment of NMIBC in clinical setting. The laser system and its light delivery mechanism enable both focused illumination of localized papillary lesions and overall illumination of the entire bladder to cover possible scattered CIS lesions. Clinicians have been consulted on feasibility of different illumination modes and other practical matters related to e.g., treatment duration. The optimization of Modulight’s system for NMIBC has also included compatibility testing with flexible cystoscopes and investigation of the light delivery system performance in bladder-like environment. Connectivity features of the laser system have been tailored to support documentation requirements in clinical trials by enabling treatment configuration and realized treatment log storage in Modulight Cloud.

show abstract

Configurable multi-wavelength laser light engine for endoscopic fluorescence imaging

Cited by 2 publications

References 6 publications

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

Optimization of light delivery for non-muscle invasive bladder cancer PDT

Contact Info

Product

Resources

About